DALLAS, July 13, 2009 (GLOBE NEWSWIRE) -- BeaconEquity.com announces an investment report featuring XOMA Ltd. (Nasdaq:XOMA). The report details XOMA's position in the biotechnology industry, comparative, financial and investment analysis, and pertinent industry information you need to know to make an educated investment decision.
The investment report on XOMA Ltd. (Nasdaq:XOMA) should be of particular interest to other biotechnology companies: Akorn Inc. (Nasdaq:AKRX), Dyax Corp. (Nasdaq:DYAX), QLT Inc. (Nasdaq:QLTI) and Enzon Pharmaceuticals Inc. (Nasdaq:ENZN).
The report is available at: http://www.beaconequity.com/i/XOMA
Get our alerts BEFORE the rest of the market. Follow us on Twitter: http://twitter.com/BeaconEquity
XOMA Ltd. is a biopharmaceutical company that discovers, develops and manufactures therapeutic antibody and other agents designed to treat inflammatory, autoimmune, infectious and oncological diseases.
Read and post on Twitter and top Stock Message Boards for these stocks and more, all in real-time: http://www.BoardCentral.com/
In the report, the analyst notes:
"XOMA continues to seek opportunities to collaborate and license its novel antibody technologies. The Company's development successes, Lucentis, Raptiva and Cimzia, indicate the potential of Company's research team and offer decent chances for another success with XOMA 052. The potential to treat many diseases, including diabetes, rheumatoid arthritis, acute gout, systemic juvenile idiopathic arthritis (sJIA), and cardiovascular disease, makes XOMA 052 a blockbuster drug candidate. ...
"Data from a phase I study of type 2 diabetes are encouraging, with patients across multiple dose groups showing evidence of biological activity. ... There's a lot more work to do on XOMA 052, including new multi-dosing studies. If successful, it would be revolutionary if the drug, given intravenously once a month is proven to work against diabetes."
To read the entire report visit: http://www.beaconequity.com/m/
BeaconEquity.com is one of the industry's largest small-cap report providers. Beacon strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on Beacon Research, please visit http://www.BeaconEquity.com
Beacon Equity Disclosure
DO NOT BASE ANY INVESTMENT DECISION UPON ANY MATERIALS FOUND ON THIS REPORT. We are not registered as a securities broker-dealer or an investment adviser either with the U.S. Securities and Exchange Commission (the "SEC") or with any state securities regulatory authority. We are neither licensed nor qualified to provide investment advice. BeaconEquity Research nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. The information contained in our report is not an offer to buy or sell securities. We distribute opinions, comments and information free of charge exclusively to individuals who wish to receive them.